Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

[1] Michelson JB(1982)Behçet’s disease Surv Ophthalmol 26 190-203

[2] Chisari FV(2000)Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 130 492-513

[3] Jabs DA(1994)The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice Invest Ophthalmol Vis Sci 35 3884-3889

[4] Rosenbaum JT(1996)Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming Invest Ophthalmol Vis Sci 37 2211-2218

[5] Foster CS(1992)Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Behçet’s disease Nippon Ganka Gakkai Zasshi 96 1282-1285

[6] Holland GN(1995)The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 15-25

[7] Jaffe GJ(1995)Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 251-259

[8] Louie JS(1999)Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932-1939

[9] Nakamura S(2002)Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541-1549

[10] Yamakawa T(2004)Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 534-542

[1] Michelson JB(1982)Behçet’s disease Surv Ophthalmol 26 190-203

[2] Chisari FV(2000)Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 130 492-513

[3] Jabs DA(1994)The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice Invest Ophthalmol Vis Sci 35 3884-3889

[4] Rosenbaum JT(1996)Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming Invest Ophthalmol Vis Sci 37 2211-2218

[5] Foster CS(1992)Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Behçet’s disease Nippon Ganka Gakkai Zasshi 96 1282-1285

[6] Holland GN(1995)The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 15-25

[7] Jaffe GJ(1995)Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 251-259

[8] Louie JS(1999)Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932-1939

[9] Nakamura S(2002)Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541-1549

[10] Yamakawa T(2004)Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 534-542